Hansa Medical announces prospectus

Important information
The information in this press release is not directed at persons located in
Australia, Canada, Hong Kong, Japan, New Zealand, the Republic of Korea,
Singapore, South Africa, Switzerland, the United States or any other country
where the offer or sale of subscription rights, interim shares or new shares is
not permitted. The information may not be published or distributed, directly or
indirectly, in or into, any of the aforementioned countries or any other country
where such action is wholly or partially subject to legal restrictions or where
such action would require additional prospectuses, other offer documentation,
registrations or other actions in addition to what follows from Swedish law. Nor
may the information be forwarded, reproduced or disclosed in such a manner that
contravenes such restrictions or gives cause to such requirements. Failure to
comply with these instructions may result in a violation of the United States
Securities Act of 1933, as amended (“Securities Act”) or laws applicable in
other jurisdictions.

The information in this press release does not contain or constitute an
invitation or an offer to acquire, sell, subscribe for or otherwise trade in
shares, subscription rights or other securities in Hansa Medical AB. No
subscription rights, interim shares or new shares will be registered under the
Securities Act or in accordance with any other rules or regulations in any other
country than Sweden and may not be transferred or offered for sale in the United
States or any country where such transfer or offer may be prohibited, or to
persons resident in any such country or on account of such persons, other than
pursuant to an exemption from, or in a transaction not subject to, the
registration requirements of the Securities Act or similar legislation in
another country, respectively.
The Board of Hansa Medical AB (publ) has prepared a prospectus for the purpose
of the rights issue, which was announced on February 23, 2015. The prospectus
has today, March 17, 2015, been approved by and registered with the Swedish
Financial Supervisory Authority (Sw. Finansinspektionen) in accordance with the
Financial Instruments Trading Act (Sw. lagen (1991:980) om handel med
finansiella instrument).

The prospectus is available on Hansa Medical’s website (www.hansamedical.com)
and Carnegie Investment Bank AB’s website (www.carnegie.se) and will be
available on the Swedish Financial Supervisory Authority’s website
(www.fi.se/Register/Prospektregistret).

The prospectus contains revised financial statements of historical financial
information regarding the financial years of 2012 and 2013, which have been
audited by the company’s auditor. Furthermore, the prospectus contains reviewed
interim financial information as at 31 December 2014 and the twelve-month period
which ended on this day, including notes to the financial information. The
information in the notes for the three financial years is partly not previously
disclosed. As earlier announced, the company’s annual report of 2014 will be
published on March 23, 2015.

The proceeds form the rights issue will be used for financing pivotal
development activities regarding IdeS, preclinical development of second
generation IdeS and evaluate development opportunities for EndoS.

About IdeS
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that
cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and
efficiently. IdeS has been tested for safety and efficacy in numerous in vitro
and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects
was conducted, demonstrating IdeS as efficacious and well tolerated with a
favorable safety profile. During 2014 and 2015, a Phase II clinical trial in
sensitized patients awaiting kidney transplantation has been conducted.
Preliminary data shows that IdeS has very good efficacy in highly sensitized
patients on the kidney transplant waitlist. The study shows that IdeS has the
capacity to make sensitized patients eligible for transplantation by decreasing
HLA antibodies to levels acceptable for transplantation. In addition to
transplantation, IdeS has potential indications within a variety of rare
autoimmune diseases including anti-GBM disease. IdeS is protected by several
patents and has been published in numerous peer review journals.

The information in this press release is disclosed pursuant to the Securities
Markets Act or the Financial Instruments Trading Act. The information was
released for public disclosure on March 18, 2015 at 10.15 CET.
For further information, please contact:
Hansa Medical AB
Göran Arvidson, CFO and acting CEO
Mobile: 46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com
About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused
on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading
enzyme in clinical development, with potential use in transplantation and rare
autoimmune diseases. Other projects include HBP (a market introduced diagnostic
marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in
pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's
share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB
as Certified Adviser.